Your Antibodies for Therapy
Providing the antibodies to meet
your target validation assays
MAbQi delivers readily developable human antibodies for your pipeline
(*) > 30 (academic) programs including: GPCR agonists, enzyme inhibitors, anti-splicing-variants, anti-post-translational modifications, anti-receptor tyrosine kinases, anti-ligand, … (many of them cross-reactive human/mouse)
Mabqi, founded upon best
in class technology from Inserm,
is a biotech company with an integrated
approach to develop human antibodies.
Follow Pierre Martineau, Director of Research at Inserm and have a look at Mabqi’s origin as creator of tailored antibodies. Know more about how started the company, what are its economic model and its ambitions for 2023. Read the article
Come and visit Mabqi at booth 15 during the 10th Antibody Industrial Symposium - June 28-29, 2022 in #Montpellier (France).Get all the information and register at https://aiscongress.com/
Mabqi and its employees strongly condemn the Russian invasion and the war waged in Ukraine, leading to suffering and chaos in Europe. In support for the Ukrainian populations affected by the current crisis, Mabqi has decided to take actions for the French Red Cross and has donated 10 000 euros for humanitarian aid.